Cardinal Health (NYSE: CAH) has reached an agreement with the Centers for Disease Control and Prevention (CDC) to act as a network administrator in Phase 2 of the Federal Pharmacy Partnership Strategy for COVID-19, which will enable retail independent, small chains and long-term care pharmacy customers to participate in the vaccination effort. Read More »

Eli Lilly and Company's (NYSE: LLY) Humulin® R U-500 administered via an investigational insulin pump (Omnipod® U-500™ Insulin Management System) provided greater A1C reduction with less daily insulin needed compared to multiple daily injections (MDI) in adults with type 2 diabetes on high dose insulin (201-600 units/day). Read More »

Eli Lilly and Company (NYSE: LLY) today announced that the U.S Food and Drug Administration (FDA) has granted approval for a new indication for ALIMTA® (pemetrexed for injection) in combination with carboplatin and KEYTRUDA® (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status. . Read More »

Eli Lilly and Company (NYSE: LLY) announced today that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period Read More »

Eli Lilly and Company (NYSE: LLY) and Indiana University's Richard M. Fairbanks School of Public Health at IUPUI announced today the launch of a new neighborhood-based, data-driven pilot in Indianapolis to help address the high incidence of diabetes Read More »

With its identity coined by the founding optometrist’s own child, RevolutionEYES’ “Little Eyes” recently opened in Carmel, Indiana, launching a pediatric eye care clinic caring for youngsters between 6 months and 13 years old. Read More »

MD Logistics, a third-party logistics company that works with pharmaceutical companies, will expand its Indiana operations, creating 50 new jobs in the process. Read More »

Zimmer Biomet Holdings' Gel-One Cross-linked Hyaluronate has been approved by the U.S. Food and Drug Administration. Read More »

The U.S. FDA has issued a letter in response to the New Drug Application for baricitinib, rejecting the application. Read More »

Eli Lilly & Co. has updated the label of Trulicity, a drug used to help control Type 2 diabetes, to state that the drug may be used in combination with insulin. Read More »

The FDA has extended the review period for Baricitnib, a new once-a-day drug for rheumatoid arthritis. Read More »

A new trend in communications is on the verge of creating a health care revolution, according to one rehabilitation clinic spokesperson. Read More »

Eli Lilly and Co., along with Incyte Corp., have announced that baricitinib received a positive opinion as well as a recommendation for approval from the European Medicines Agency Committee for Medicinal Products for Human Use. Read More »

Eli Lilly and Co.'s EXPEDITION3 clinical study involving solanezumab failed to meet its primary goal in treating Alzheimer’s. Read More »

Eli Lilly and Co.'s analysis of its Phase 3 baricitinib trial efficiency and safety data, as well as that of other Phase 2 trials, will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, which is being held on Nov. 11-16 in Washington, D.C. Read More »

Eli Lilly and Co. has launched an innovative new plan to increase the access of quality health care and to see the improvement of long-term health care for millions of individuals on a global scale. Read More »

The Arthritis Foundation, in association with Eli Lilly and Co., has launched a new initiative called “Living Your Yes With RA.” Read More »

Eli Lilly and Co. will present data at the European Society of Medical Oncology’s 2016 Congress in Copenhagen from a number of clinical studies that will serve to further strengthen the development of its diverse clinical cancer portfolio. Read More »

Eli Lilly and AstraZeneca recently released a joint announcement revealing that the two companies have received Fast Track designation for the AZD3293 Alzheimer’s disease development program from the U.S. Food and Drug Administration (FDA). Read More »

Dr. Levi Garraway has been appointed SVP of Global Development & Medical Affairs for the oncology business at Eli Lilly and Company. Read More »